NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Decoy Therapeutics Inc. DCOY
11 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-129.10
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-338.3%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 11-year series below
Revenue
Net income
Per share
USD -129.10
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-338.3%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-177.8%
Each USD of equity lost 338 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 11.1M
total assets, end of FY2025
Total assetsUSD 11.1M
EquityUSD 5.9M
CashUSD 10.7M
Current ratio2.13×
Equity funds 53% of total assets.
History
11 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue $B
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
·
·
·
·
·
0.0
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−129.10
−69.54
−30.74
−14.88
−7.72
−0.50
−2.12
−1.16
−1.99
−2.43
−2.08
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
−0
−2
−0
·
·
·
ROE %
−338.3
−164.0
−160.1
−128.7
−41.9
−44.9
−149.0
·
−122.1
−52.1
−68.0
Shares out B
·
0.00
0.00
0.00
0.00
0.02
0.00
0.00
0.02
0.02
0.02
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
35 of 35
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed